ClinicalTrials.gg

Program

ARD-885

A development code. Also written as “ARD-885 Tablets”.

Its studies are mostly in Arthritis, Rheumatoid, led by Artivila (Shenzhen) Innovation Center.

Furthest: phase 1, since Nov 14, 20251 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Artivila (Shenzhen) Innovation Center10 open or runningphase 1since Nov 14, 2025Nov 14, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 14, 2025First study: phase 1 study in Arthritis, RheumatoidFirst studyNCT07266207 · 94 enrolled · China

TargetBeta

IRAK1 →IRAK4 →read by rule
“ARD-885 Tablet is a dual-target inhibitor of IRAK4 and IRAK1.”study text, by rule · the study

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07266207Arthritis, Rheumatoid · China1CompletedAug 14, 202594

How it is read

Names in the registry

  • “ARD-885 Tablets”, 1 entry

Codes read as this program: ARD885.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.